Abstract
Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 71-75 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 197 |
Issue number | 1 |
DOIs | |
State | Published - Apr 2022 |
Keywords
- immunotherapy
- metabolism
- non-Hodgkin lymphoma
- quality of life
- risk factors
ASJC Scopus subject areas
- Hematology